- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02963740
Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors
January 9, 2022 updated by: Carol Fabian, MD, University of Kansas Medical Center
Feasibility of High Levels of Energy Expenditure From Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors
The purpose of the study is to demonstrate that breast cancer survivors who need to lose weight are able to follow a weight loss program which combines modest calorie restriction with a graduated activity program..
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Feasibility will be assessed by 1) the number of women that complete the 3--month program; 2) the number of women that can achieve the targeted amount of physical activity per week by the end of the program; and 3) the median amount of physical activity achieved group by all subjects that complete the program.
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 71 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women < age 71 in good general health.
- Prior diagnosis of breast cancer.
- At least 3 months from completion of any cytotoxic chemotherapy or radiation or surgery. May continue to take endocrine therapy and/or maintenance trastuzumab.
- Body Mass Index (BMI) 30-45 kg/m2.
- By self-assessment, currently performing 60 minutes or less of purposeful exercise per week but able to walk at least 30 minutes on a level surface.
- Access to a smart phone capable of running MyFitnessPal and Garmin Connect apps and willing to have diet and exercise data from these apps viewed by study personnel.
- Live in the greater Kansas City Metropolitan Area
- Willing and able to perform moderate intensity exercise at least 5 days per week for 3 months.
- Willing to perform unsupervised home exercise for the entire 3 months.
- Willing to participate in a weekly behavioral modification group phone call for 3 months.
- Willing to participate in a controlled dietary intervention with portion controlled meals and partial meal and track food intake and exercise.
Exclusion Criteria:
- Use of metformin, insulin, steroids or weight loss or anti-psychotic drugs within the prior 3 weeks
- Individuals with prior bariatric surgery procedures
- Need for chronic immunosuppressive drugs
- Participation within the past 6 months on a structured weight loss program such as Weight Watchers®
- Physical impairments (bad hip, knees, feet, peripheral neuropathy) that would prohibit performing moderate intensity exercise at least 5 days per week.
- Any other condition or intercurrent illness that in the opinion of the investigator makes the subject a poor candidate for participation in the trial such as recent cardiac event.
- Currently receiving investigational agents in a clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Weight Loss Intervention Group
Participants will take part in supervised exercise and home-based exercise sessions.
Participants will be asked to follow a specific diet.
Participants will be asked to take part in weekly behavioral group phone calls.
|
Participants will take part in supervised exercise activities two times per week at a YMCA.
Length of the activity will be increased during participation in study.
Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
Aerobic exercise activities to be completed at home.
Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
Once weekly phone calls that are group-based.
The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to supervised exercise sessions
Time Frame: Week 12
|
Adherence is defined as the percent of monitored sessions at the YMCA attended by the participant.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent participants meeting physical activity goal
Time Frame: Week 9 to Week 12
|
Measured as percentage of participants meeting final physical activity goal between week 9 to week 12. Measurement based off activity tracker participants will wear.
|
Week 9 to Week 12
|
Compliance with group telephone sessions
Time Frame: Week 12
|
Defined as number of participants attending at least 75% of the weekly group calls.
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Carol Fabian, MD, University of Kansas Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (Actual)
March 1, 2017
Study Completion (Actual)
March 1, 2017
Study Registration Dates
First Submitted
November 10, 2016
First Submitted That Met QC Criteria
November 10, 2016
First Posted (Estimate)
November 15, 2016
Study Record Updates
Last Update Posted (Actual)
January 25, 2022
Last Update Submitted That Met QC Criteria
January 9, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004575
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
Clinical Trials on Supervised Exercise
-
Hull University Teaching Hospitals NHS TrustCompletedAbdominal Aortic AneurysmUnited Kingdom
-
University of ManchesterUnknownCardiovascular Diseases | Peripheral Arterial Disease
-
Universidad de AlmeriaCompletedLow Back Pain | Physical ActivitySpain
-
Medical University of ViennaUnknownPeripheral Artery DiseaseAustria
-
Hasselt UniversityRecruitingGestational Hypertension | Cardiovascular Pregnancy ComplicationBelgium
-
University Health Network, TorontoCompletedProstate CancerCanada
-
Grupo Rehabilitacion en SaludClinica Las AmericasCompletedChronic Heart FailureColombia
-
Ahram Canadian UniversityRecruiting
-
Northwestern Health Sciences UniversityHealth Resources and Services Administration (HRSA); Berman Center for Outcomes...Completed
-
Istanbul University - Cerrahpasa (IUC)RecruitingAmyotrophic Lateral SclerosisTurkey